

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number  
**WO 2004/065601 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/11,  
A61K 31/713, A61P 31/14

(21) International Application Number:  
PCT/US2004/001461

(22) International Filing Date: 21 January 2004 (21.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
103 02 421.2 21 January 2003 (21.01.2003) DE

(71) Applicant (for all designated States except US): ALNY-  
LAM EUROPE AG [DE/DE]; Fritz-Hornschuch-Str. 9,  
95326 Kulmbach (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HADWIGER,  
Philipp [DE/DE]; Almstr. 5, 95488 Bayreuth (DE).  
JOHN, Matthias [DE/DE]; Kappellenstr. 12, 96103  
Hallstadt (DE). LORENZ, Christina [DE/DE]; Nobelstr.

31, 95444 Bayreuth (DE). VORNLOCHER, Hans-Peter  
[DE/DE]; Lise-Meitner-Platz 4, 95448 Bayreuth (DE).  
KREUTZER, Roland [DE/DE]; Glotzdorf 26, 95466  
Weidenberg (DE). LIMMER, Stefan [DE/DE]; Am  
Buttergraben 11, D-95326 Kulmbach (DE). WILLIAMS,  
Kathleen, Madden [US/US]; 10 Nathaniel Guild Road,  
Sharon, MA 02067 (US).


(74) Agent: GYURE, Barbara, A.; Palmer & Dodge LLP, 111  
Huntington Avenue, Boston, MA 02199-7613 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID



(57) Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having improved efficiency of inhibition of gene expression, methods of making the dsRNA, and pharmaceutical compositions comprising the dsRNA. The dsRNA comprises an RNA strand (complementary RNA strand) having a region which is complementary to an RNA transcript of at least a part of a target gene, and at least one covalently linked lipophilic group. The dsRNA are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.



GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
18 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.